Transgene Biotek Limited, a biotechnology company, provides research and development services for bulk drugs in India. It offers a portfolio of oncology drugs, oral drug delivery, and biogenerics. The company provides TrabiDHA for use in health food, baby food/formula, health supplement, and chicken and animal feed markets; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. The company was incorporated in 1990 and is based in Sangareddy, India.
| Current Price | ₹3.28 |
|---|---|
| Market Cap | ₹22 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology |
| Sub-Industry | Biotechnology > 0 |
| P/E Ratio | -13.5 |
| Return on Equity | -17.96% |
| 52-Week Range | ₹1.83 – ₹5.26 |
| Beta (1Y) | 1.13 |
Transgene Biotek Ltd. is trading at ₹3.28, with a market capitalisation of ₹22 Cr.
Transgene Biotek Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology space (Biotechnology > 0).
Transgene Biotek Ltd. has a P/E of -13.5 and a return on equity of -17.96%.